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     Abstract   
Background: Five multi-center randomized controlled trials have shown superior outcomes for mechanical 
thrombectomy to standard intravenous thrombolysis for acute anterior ischaemic stroke. This idea-paper aims to 
provoke multi-disciplinary expertise to develop a less invasive and more rapid thrombectomy technology. The 
hypothesis is that by adapting existing technology to magnetize in vivo blood clots, we should be able to dislodge 
clots from major vessels magnetically and achieve minimally invasive reperfusion.   
Methods: First, magnetized antibodies against specific epitopes in blood clots must be developed (such as the 
previously used Fibrin Beta-chain specific antibody, 59D8) and an external portable magnetic device with 
superlens magnetic-field focusing would be used to dislodge and guide the clot proximally to establish reperfusion; 
subsequently, the clot will be removed. A distal magnet, statically held at the original location of the dislodged clot, 
would prevent microemboli from occluding distal vessels during dislodgement and removal of the clot. 
Conclusion: Developing specific antibodies against in vivo blood clots (immunology) with attached 
superparamagnetic nanoparticles (nanoscience) and an external portable magnetic device with a focused magnetic 
flux (applied medical physics) will significantly improve time to revascularization in acute ischaemic stroke, 
minimize risks of intervention, and thus improve outcomes further. 
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Background   
Ischaemic stroke is a leading cause of mortality and morbidity 
in the world, and constitute 85.0% of all strokes, costing the UK 
National Health Service (NHS) over £3billion a year [1]. In 
vivo, acute blood clots may be visualized on Computed-
Tomography (CT) scans as hyperdense and radio-opaque to X-
rays. Intrinsically, the blood clot has chemically altered blood 
components which arise as a result of the coagulation cascade 
and platelet adhesion and aggregation. 
    Intravenous or intra-arterial thrombolysis with recombinant 
tissue-plasminogen activators (e.g., alteplase) have remained 
the gold-standard hyperacute treatment of ischaemic stroke, and 
previously were the standard of treatment for ST-elevation 
myocardial infarctions prior to primary percutaneous coronary 
intervention. 
  Several studies have shown a modest benefit of thrombectomy 
interventions. In meta-analyses and subgroup analysis, invasive 
neuro-radiologically performed thrombectomies are of most 
benefit the earlier they are performed and in patients with more 
severe strokes as quantified on the National Institutes of Health 
Stroke Scale (NIHSS) scores [2]. Five multi-center, randomized 
controlled trials have shown mechanical thrombectomy devices 
to be superior (outcomes on the modified Rankin Scale at 90 
days) to standard treatment with intravenous thrombolysis alone 
(in anterior circulation ischemic stroke caused by a proximal 
large artery occlusion) [3-7]. 
     The procedures themselves carry risk and benefit is limited 
due to dependence on expertise, speed of transfer to a centre 
capable of vascular intervention as well as time required for the 
preparations for intervention. Therefore, developing a non-
invasive technique that can dislodge and remove clots would 
improve time to thrombectomy, enhancing benefits, and reduce 
risks associated with mechanical thrombectomy. 
 
Methods 
Overview 
What is proposed here is to develop antibodies specifically 
against an epitope restricted to in vivo blood clots. The 
Fragment crystallizable (Fc) region of the antibody would be 
pre-attached to superparamagnetic nanoparticles. 
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After intravenous or intra-arterial administration of this 
magnetized antibody, a non-invasive transcutaneous external 
magnet would be applied to the region of the clot, for example, 
for carotid occlusions. The externally applied magnetic field 
would be varied in order to dislodge the clot from the vessel, 
with the option of using ultrasound to assist the mechanical 
dislodging. 
     A second bolus of magnetized antibody would then be 
injected to coat the clot further as more epitopes are revealed 
during dislodgement. The magnetic field can then guide the clot 
against arterial blood flow towards a more proximal superficial 
artery, thus establishing reperfusion - while a more distal 
magnet remains to catch any microemboli dislodged from the 
clot. An arterial puncture can then be performed to remove the 
clot entirely (in later iterations, instead of arterial puncture, 
intra-arterial thrombolysis and/or ultrasound could conceivably 
be used to break the clot in situ). 
 
1. Antibodies 
1a. Super-paramagnetic-nanoparticles (MNP)  
These have already been used for magnetized drug delivery. 
Although high loadings (>100 μg/mL) of MNPs cause 
cytotoxicity, toxicity studies on magnetic nanoparticles show 
that these particles can be biocompatible [8]. 
 
1b. In vivo blood clot specific epitope (Fibrin)  
In studies performed in the late 1980s, Fibrin Beta chain-
specific antibody 59 D8 – which provided the highest level of 
binding to clot – binds fourteen-fold better to blood clots than 
the control (antidigoxin antibody) [9].  Fibrin would thus be the 
most likely candidate for a specific epitope. Other blood clot 
epitopes could be considered if anti-Fibrin antibodies are 
deemed insufficiently specific for blood clots after testing. 
 
2. Transcutaneous Portable Magnetic Device (TPMD) 
Recently the Food and Drug Administration (FDA) in the USA 
issued a substantial equivalence approval for a portable 
magnetic resonance imaging scanner (MRI). This low magnetic 
field scanner can provide images of the brain [10].  
     A similar bespoke device would be required for this purpose, 
a portable high-field machine, to be applied via the 
transcutaneous route after the clot is magnetized. 
     Alternatively, a device integrated into an MRI scanner to 
automate the process and localize the clot, akin to radiotherapy 
preparation. 
 
2a. Magnetic flux focusing and portability 
In order to increase the magnetic force on the clot with 
increased chances of dislodgement and reperfusion, besides an 
advanced integrated version within MRI-stroke specific 
scanners, the portable external magnet can utilize the following 
design concepts: 
i) Solenoid: increased magnetic flux within the solenoid. It 
would be difficult to access the clot from the carotid. Thus, a 
superlens design is preferable (see below). 
ii) By focusing on a magnetic field, the size of the TPMD could 
be reduced, and a smaller electric power source would be 
required than would be feasible with the magnetic field of an 
unfocused magnet [11]. This allows for miniaturization and a 
portable TPMD, which may be used even in the emergency 
department itself – thus substantially reducing the preparation 
time required for mechanical thrombectomy in an angiography 
suite. 
iii) Superlens metamaterials with magnetic permeability of ¬-1 
can focus the near fields of magnetic flux and improve 
efficiency, allowing for a smaller, more portable TPMD [12]. 
 
2b. Dynamic Magnetic field to dislodge the clot (prior to the 
second injection of magnetized Antibody) 
There will be a need for mechanical, magnetic, ultrasonic, or 
combined mechanisms to help dislodge the clot. This may be 
achieved by: 
i) altering the strength of the TPMD magnetic-field focused on 
the magnetized clot 
ii) moving the portable external magnet to alter the distance 
between it and the magnetized clot. This can be an automated 
mechanical process occurring in the hand-held device. While 
the portable device is held constant, the external magnet within 
it moves. 
iii) An electrically controlled alternating magnetic field, similar 
to that used in MRI. These field-altering methods may not be 
sufficient to dislodge the clot. A mechanical or ultrasonic 
component may be required. 
 
3. Magnetic Microemboli Filter (MMF) 
The MMF would be a straightforward permanent magnet which 
occupies the original location of the clot. After the TPMD has 
dislodged the clot and is guiding it proximally, the MMF would 
prevent arterial blood flow from throwing microemboli off the 
retrieved clot more distally. The MMF would magnetically 
prevent distal micro-embolization during dislodgement and 
removal of the clot by the TPMD. 
 
Discussion 
The key to better outcomes in strokes is rapid thrombectomy or 
thrombolysis, with the former showing improved outcomes, 
especially when clots are retrieved without delay. Within a few 
minutes of hypoxia or lack of blood flow, nervous tissue begins 
to die.  
     Current thrombectomy procedures puncture the skin and 
artery, whether in the leg (femoral) or arm (radial), and a clot 
retrieval device is advanced up towards the heart and then into 
the blocked artery. Risks include pulmonary embolism, embolic 
strokes, infection, and damage to the blood vessel at the site of 
the clot. The combined methodology outlined above has the 
potential to not only expedite interventions but also minimize 
risks due to no clot retrieval device being advanced into the 
arterial system. This is achieved by a hand-held TPMD that can 
be used immediately after magnetized antibody injection, 
reducing the duration of the ischaemic brain. 
     Further work based on the specifics of the antibody and 
TPMD capability will be required in the form of a theoretical 
calculation of required magnetic field strength of the TPMD 
using fluid mechanics. It will be necessary and may be possible, 
using the data below, to determine the theoretically required 
TPMD field-strength in order to magnetically hold on to the 
clot and steer it against blood flow:  
i) Antibody specificity to blood clots.  
ii) MNP strength.   
iii) Arterial blood flow dynamics, e.g., in carotid arteries  
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iv) Vessel and blood clot distance from the external magnetic 
device (ultrasound estimation of soft tissue thickness between 
skin and vessel).  
     Furthermore, a calculation is required using the above data 
to ensure there are no major shearing forces on other organs 
(e.g., endothelial cells of intact patent vessels) to minimize side 
effects from less specifically bound MNP around the body. For 
example, using Fibrin beta-chain specific antibodies, we would 
need to ensure that these are sufficiently specific to prevent 
significant binding of the magnetized antibodies to other 
tissues. 
 
Conclusion  
The outlined innovative method has the potential to improve 
ischaemic and embolic stroke outcomes. 
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